Tirzepatide

Tirzepatide is a lab-made peptide (research code LY3298176) that copies two gut hormones at once, GIP and GLP-1 — a design sometimes called a 'twincretin.' It is supplied here as an analytical-grade reference material for laboratory research use only.

A dual agonist is one molecule that activates two different receptors. Tirzepatide engages both the GIP and GLP-1 receptors; laboratory studies describe it as 'biased' and 'imbalanced' because it does not stimulate the two receptors equally. Researchers study that balance to understand its effects.

Yes. It has been tested in large randomized trials (the SURPASS and SURMOUNT programs) covering blood-glucose control, body-weight change, and metabolic fatty-liver disease, and it has since been approved as a medicine. That makes its evidence base unusually strong for a research peptide, though the trial benefits came with gastrointestinal side effects.

Semaglutide acts on a single receptor (GLP-1); tirzepatide acts on two (GIP and GLP-1). A head-to-head trial compared the two directly for body-weight change in adults with obesity. Both are studied heavily in metabolic research.

Those are approved medicines that contain tirzepatide. What we supply is analytical-grade tirzepatide reference material for laboratory research use only — it is not a medicine, is not for personal use, and nothing here is medical or dosing advice.